Sarah Eckles van Horn, APRN
Acute Care · Lincoln, NENPI 1740362763
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 86 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $791, 5.6 times the $141 reported in 2022.
Across 86 payments — averaging $21.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$349
- UCB, Inc.$204
- Lundbeck LLC$142
- Abbott$93
- EMD Serono, Inc.$87
- SK Life Science, Inc.$87
- plus $905 from 26 others
What the payments were for
- Food & beverage$1,867100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 17 | $349 |
| UCB, Inc. | 9 | $204 |
| Lundbeck LLC | 3 | $142 |
| Abbott | 6 | $93 |
| EMD Serono, Inc. | 4 | $87 |
| SK Life Science, Inc. | 4 | $87 |
| Biogen | 4 | $83 |
| Medtronic | 2 | $71 |
| Novartis | 4 | $70 |
| GE HealthCare | 3 | $61 |
| Argenx US, Inc. | 2 | $57 |
| ANI Pharmaceuticals, Inc. | 2 | $54 |
| Genentech USA, Inc. | 2 | $42 |
| Acadia Pharmaceuticals Inc | 2 | $40 |
| Tonix Medicines, Inc. | 2 | $38 |
| Pfizer | 2 | $37 |
| AstraZeneca(2 entities) | 2 | $37 |
| Amgen | 1 | $31 |
| Johnson & Johnson | 2 | $30 |
| Boston Scientific | 1 | $30 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Upsher-smith Laboratories LLC | 1 | $21 |
| Hospira, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Avion Pharmaceuticals | 1 | $18 |
| CSL Behring | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
How this compares
$1,867 in reported general payments places this provider in the 80th percentile of 103 acute care providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 65 | $943 |
| Donepezil Hcl | 83 | $591 |
| Atorvastatin Calcium | 91 | $549 |
| Pregabalin | 23 | $516 |
| Levetiracetam | 50 | $330 |
| Memantine Hcl | 24 | $280 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 15 | $222 |
| Topiramate | 19 | $202 |
| Duloxetine Hcl | 13 | $177 |
| Primidone | 16 | $157 |
| ClopidogrelClopidogrel Bisulfate | 12 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Upsher-smith Laboratories LLCTopiramate | $21 | $20219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 103 acute care providers in Nebraska.
Other acute care in Lincoln
- William SaalfeldLincoln$115K
- Sarah SchroederLincoln$6K
- Vicki NortonLincoln$3K
- Beth BreyLincoln$2K
- Simone MartinLincoln$2K
- Amanda HallLincoln$2K
- Megan StittLincoln$1K
- Beth CuetoLincoln$1K
- Sara KleinLincoln$702
- Cassandra MuellerLincoln$613
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.